AU2019335366A1 - Imidazoquinoline compounds and uses thereof - Google Patents

Imidazoquinoline compounds and uses thereof Download PDF

Info

Publication number
AU2019335366A1
AU2019335366A1 AU2019335366A AU2019335366A AU2019335366A1 AU 2019335366 A1 AU2019335366 A1 AU 2019335366A1 AU 2019335366 A AU2019335366 A AU 2019335366A AU 2019335366 A AU2019335366 A AU 2019335366A AU 2019335366 A1 AU2019335366 A1 AU 2019335366A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
alkyl
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019335366A
Other languages
English (en)
Inventor
Lihu Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Birdie Biopharmaceuticals Inc Cayman Islands
Original Assignee
Birdie Biopharmaceuticals Inc Cayman Islands
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Birdie Biopharmaceuticals Inc Cayman Islands filed Critical Birdie Biopharmaceuticals Inc Cayman Islands
Publication of AU2019335366A1 publication Critical patent/AU2019335366A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2019335366A 2018-09-07 2019-09-05 Imidazoquinoline compounds and uses thereof Abandoned AU2019335366A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862728556P 2018-09-07 2018-09-07
US62/728,556 2018-09-07
PCT/US2019/049784 WO2020051356A1 (en) 2018-09-07 2019-09-05 Imidazoquinoline compounds and uses thereof

Publications (1)

Publication Number Publication Date
AU2019335366A1 true AU2019335366A1 (en) 2021-03-25

Family

ID=69722888

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019335366A Abandoned AU2019335366A1 (en) 2018-09-07 2019-09-05 Imidazoquinoline compounds and uses thereof

Country Status (9)

Country Link
US (1) US20210214354A1 (https=)
EP (2) EP4306523A3 (https=)
JP (1) JP2022501327A (https=)
KR (1) KR20210074290A (https=)
CN (1) CN113164460A (https=)
AU (1) AU2019335366A1 (https=)
CA (1) CA3111786A1 (https=)
ES (1) ES2963112T3 (https=)
WO (1) WO2020051356A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899539B (zh) 2014-01-10 2021-11-09 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
EP3166976B2 (en) 2014-07-09 2026-04-08 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
IL312120B2 (en) 2017-06-23 2025-06-01 Birdie Biopharmaceuticals Inc Pharmaceutical compositions
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
CN115916342A (zh) * 2020-07-08 2023-04-04 普渡研究基金会 用于治疗纤维化疾病和癌症的化合物、组合物和方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US689338A (en) * 1901-03-29 1901-12-17 Nat Faucet Company Tapping-bung.
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
EP1667694B1 (en) * 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
US20080213308A1 (en) * 2004-09-14 2008-09-04 Nicholas Valiante Imidazoquinoline Compounds
US8728486B2 (en) * 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
WO2013033345A1 (en) * 2011-08-30 2013-03-07 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
MX377916B (es) * 2014-04-22 2025-03-10 Hoffmann La Roche Compuestos 4-amino-imidazoquinolina.
CN105233291A (zh) * 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
EP3166976B2 (en) * 2014-07-09 2026-04-08 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors
CN105732635A (zh) * 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
CN115350279A (zh) * 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合

Also Published As

Publication number Publication date
EP3846807B1 (en) 2023-08-02
KR20210074290A (ko) 2021-06-21
CN113164460A (zh) 2021-07-23
EP4306523A3 (en) 2024-01-24
EP3846807A4 (en) 2022-05-18
CA3111786A1 (en) 2020-03-12
JP2022501327A (ja) 2022-01-06
US20210214354A1 (en) 2021-07-15
EP3846807A1 (en) 2021-07-14
EP4306523A2 (en) 2024-01-17
ES2963112T3 (es) 2024-03-25
WO2020051356A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
EP3846807B1 (en) Imidazoquinoline compounds and uses thereof
US10822349B2 (en) Macrocyclic purines for the treatment of viral infections
US10676457B2 (en) Cyclopropylamines as LSD1 inhibitors
US10125133B2 (en) Substituted [1,2,4]triazolo[1,5-a]pyridines and substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
JP2022105091A (ja) ｃＧＡＳアンタゴニスト化合物
TWI652269B (zh) 氮雜吡啶酮化合物及其用途
CN111606861A (zh) 用于治疗病毒感染和另外的疾病的酰氨基嘧啶衍生物
CN118843629A (zh) 抗病毒化合物及其制备和使用方法
EP4172142B1 (en) Branched lipid compounds
HK40101420A (en) Imidazoquinoline compounds and uses thereof
EP3067351B1 (en) Compound having higher inhibition of protein kinase g activity and preparation method therefor
HK40057163A (en) Imidazoquinoline compounds and uses thereof
HK40057163B (en) Imidazoquinoline compounds and uses thereof
US20240246978A1 (en) Phenyldihydropyrimidine compound and use thereof
WO2023168844A1 (zh) 氘代内酰胺类化合物及其制备方法、组合物和用途
CN116120254B (zh) 13,14-双一氧化氮供体-β-榄香烯衍生物及其制备和应用
CN117003771B (zh) 一种抗流感病毒衍生物及其用途
CN121941693A (zh) 化合物及其用途
US20250353816A1 (en) Quinolines as modulators of polrmt
CN114008029A (zh) 用于治疗病毒感染和另外的疾病的喹唑啉前药
HK40067856A (en) Quinazoline prodrugs for the treatment of viral infections and further diseases
HK40036815A (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application